Health Equality and the Science of Female Aging
1.1B women will reach menopause by 2025. With perimenopause begin as early as the late 30s—this generation will live more of their lives in menopause than not. Menopause has profound effects on lifespan and long-term health, yet remains poorly researched. With fertility market success and more leadership roles for women in midlife, attention and funding are finally directed to deepen understanding and mitigate health impacts. The work ranges from prolonging reproductive span to helping women extend their overall lifespan. Researchers and founders aim to bring more health equality to women over 40, a major cultural milestone with mindblowing science behind it. This panel will cover breakthrough research, technology and opportunities for go-to-market, and implications for women and society.
Share this idea
Additional Supporting Materials
- Scientific solutions for ovarian aging is lacking. Promising new technology driven by CRISPR & organoid research now pave the path to intervention.
- The market is enormous for investors and entrepreneurs. Forbes noted that the menopause market alone is estimated to be worth $600 billion.
- Just 5% of women’s health startups—the “femtech” sector—funded in 2019 were focused on menopause. The opportunity to disrupt this market is profound.
- Christine Hall, Reporter, TechCrunch
- Alicia Jackson, CEO & Founder, Evernow
- Jennifer Garrison, PhD, Assistant Professor, Buck Institute; Founder & Faculty Director, Global Consortium for Reproductive Longevity & Equality, Buck Institute
- Martin Varsavsky, CEO & Chairman, Chairman of Inception Prelude Fertility, CEO of Overture, Goggo Network, MVB Fund, Levere Holdings
Shannon Wilsey, Director, Sparkpr